Oxipit, a Lithuanian company operating as Oxipit, UAB, develops ChestLink, an AI product that autonomously reports normal chest X-ray studies and removes them from the radiologist's worklist. The product is sold within the CXR Suite and is CE-marked in Europe for autonomous use. Oxipit was founded in 2017.
Oxipit is part of the Swedish imaging IT group Sectra following its acquisition, which Sectra announced in March 2026. Sectra states that the Oxipit team will operate as a dedicated AI development centre within its Imaging IT Solutions business. Both the company and its parent are based in the EU, so the ownership structure raises no non-EU jurisdiction question. The website does not state where customer or patient data is hosted, nor whether the product runs in the cloud or on premises, so these terms should be requested directly from the vendor.